A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.
Open access plan is no academic spring
19 July 2012
The government argues that "gold" open access will give us a competitive economic advantage. It will not. The approach as it stands will increase the cost of research but, without reciprocal international agreement, will likely offer a competitive advantage to those who do not invest in UK research.
Professor Stephen Caddick
Vice-provost (enterprise), University College London
Read the full article at www.guardian.co.uk